Price (delayed)
$4.99
Market cap
$342.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.32
Enterprise value
$264.96M
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a ...
Highlights
EYPT's equity has surged by 54% since the previous quarter and by 26% year-on-year
EYPT's quick ratio is up by 45% since the previous quarter and by 44% year-on-year
The net income has dropped by 85% year-on-year and by 26% since the previous quarter
The EPS has contracted by 27% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of EYPT
MarketValuationsEarnings
Shares outstanding
68.73M
Market cap
$342.96M
Enterprise value
$264.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
6.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.12
Revenue
$43.27M
Gross profit
$39.56M
Operating income
-$145.85M
Net income
-$130.87M
EBIT
-$130.77M
EBITDA
-$129.23M
Free cash flow
-$130.28M
Per shareBalance sheetLiquidity
EPS
-$2.32
EPS diluted
-$2.32
Free cash flow per share
-$2.31
Book value per share
$4.93
Revenue per share
$0.77
TBVPS
$7.43
Total assets
$418.47M
Total liabilities
$81.96M
Debt
$21.86M
Equity
$336.5M
Working capital
$334.26M
Debt to equity
0.06
Current ratio
7.81
Quick ratio
7.58
Net debt/EBITDA
0.6
MarginsEfficiencyDividend
EBITDA margin
-298.6%
Gross margin
91.4%
Net margin
-302.4%
Operating margin
-337.1%
Return on assets
-38.1%
Return on equity
-50.7%
Return on invested capital
-77%
Return on capital employed
-35.4%
Return on sales
-302.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EYPT stock price
How has the EyePoint Pharmaceuticals stock price performed over time
Intraday
-7.08%
1 week
-15.57%
1 month
-12.76%
1 year
-75.95%
YTD
-33.02%
QTD
-7.93%
Financial performance
How have EyePoint Pharmaceuticals's revenue and profit performed over time
Revenue
$43.27M
Gross profit
$39.56M
Operating income
-$145.85M
Net income
-$130.87M
Gross margin
91.4%
Net margin
-302.4%
EYPT financials
The company's operating margin has shrunk by 107% YoY and by 32% QoQ
The net margin has dropped by 97% year-on-year and by 33% since the previous quarter
The operating income has plunged by 94% YoY and by 25% from the previous quarter
The net income has dropped by 85% year-on-year and by 26% since the previous quarter
Growth
What is EyePoint Pharmaceuticals's growth rate over time
EYPT growth chart
Valuation
What is EyePoint Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.01
P/S
6.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.12
Price to earnings (P/E)
The EPS has contracted by 27% YoY and by 17% from the previous quarter
Price to book (P/B)
The stock's price to book (P/B) is 75% less than its 5-year quarterly average of 4.1 and 58% less than its last 4 quarters average of 2.4
EYPT's equity has surged by 54% since the previous quarter and by 26% year-on-year
Price to sales (P/S)
EYPT's P/S is 48% below its last 4 quarters average of 12.6 and 22% below its 5-year quarterly average of 8.3
The revenue has declined by 6% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is EyePoint Pharmaceuticals business performance
The ROS has plunged by 100% YoY and by 33% from the previous quarter
The ROIC has soared by 95% YoY and by 25% QoQ
EYPT's return on assets is down by 21% since the previous quarter and by 14% year-on-year
EyePoint Pharmaceuticals's ROE has decreased by 18% from the previous quarter but it has increased by 18% YoY
Dividends
What is EYPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EYPT.
Financial health
How did EyePoint Pharmaceuticals financials performed over time
Assets vs liabilities
EYPT's quick ratio is up by 45% since the previous quarter and by 44% year-on-year
EyePoint Pharmaceuticals's current ratio has increased by 43% YoY and by 42% from the previous quarter
Debt vs equity
The debt is 94% smaller than the equity
EYPT's debt to equity has soared by 200% year-on-year but it is down by 40% since the previous quarter
EYPT's equity has surged by 54% since the previous quarter and by 26% year-on-year
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.